Abstract: The present invention relates to the use of myo-inositol hexaphosphate or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or treatment of a disease associated with the dissolution of crystals of calcium salts, in particular osteoporosis. These compounds may be utilized in the manufacture of functional foods, dietetic supplements, vitamin supplements, nutritional supplements, food supplements, or phytotherapeutic products having properties of inhibition of dissolution of crystals of calcium salts.

Abstract: The invention relates to a fixed-dose association of 5 phytate and zinc in synergic proportions for use in the treatment of crystallisation of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said 10 association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallisation of hydroxyapatite in humans.

Abstract: The present invention refers to the use of germ flour of fruits selected among cereals, carob and mixtures thereof for the manufacture of food products rich in phytates for the treatment or prevention of pathological or pre-pathological conditions derived from phytate deficient states, and in particular kidney stones.

Abstract: A process is provided for evaluating the global capacity of urine to form chalky renal calculus, the process comprising the steps of pouring a sample of a recently discharged urine into a container plate bearing, on its inner bottom portion, a cup containing a reaction substrate capable of initiating crystallization of calcium in the sample, allowing the sample to rest; discarding the sample from the container plate, washing the container plate with bidistilled water and discarding the water, adding a diluted HCl solution (2.3N) and spreading it over the entire surface of the substrate contained in the cup, adding an aqueous sodium acetate solution (5% w/v) and an indicating solution of ARSENAZO III (0.1% w/v) and mixing the acetate solution and the indicating solution for 15 seconds, to obtain a stained reaction mixture which can be qualitatively and quantitatively evaluated. A kit for carrying out this process is also provided.